Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals focuses on discovering, developing, and commercializing pharmaceutical products. Its drug candidates include Sotagliflozin for heart failure and type 1 diabetes, LX9211 for neuropathic pain, and LX2761 for gastrointestinal issues. These drugs are in various stages of development, from Phase I to Phase III clinical trials. The company has partnerships with Bristol-Myers Squibb and Genentech. Lexicon was founded in 1995 and is headquartered in Texas.

Overview

Sector

Biotechnology

Target Price

0.0 USD

Current Price

1.2 USD

Potential

-100%

Strengths

Price to book ratio (2.92) is lower than the sector mean (24.44).

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.
The company has high debt. Net Debt to EBITDA Ratio (100.00) is higher than the sector mean.
The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
EBITDA Margin (0.00%) appears relatively low.

Key Financial Data

Indicator	Value
PER	100.0
EV/EBITDA	100.0
Price/Free Cash Flow'	100.0
ROIC	-%
Net Debt/EBITDA	100.0